Loading
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 13 May 2025 for Lexicon Pharmaceuticals, INC..
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Judith L. Swain: trading record in brief
This profile gathers the share dealings of Judith L. Swain across 2 companies, led by Lexicon Pharmaceuticals, Inc. and Prometheus Biosciences, Inc. In total, 15 filings cover trades dated from 27 April 2012 to 13 May 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 13 May 2025 came the latest disclosure, an option exercise in Lexicon Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Judith L. Swain
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
36,810 shares0Common StockSEC:0001127602-25-014146:0
8,032 shares0Common StockSEC:0001127602-24-013558:0
2,071 sharesCommon StockSEC:0000899243-23-015756:0
9,302 shares0Common StockSEC:0001127602-23-016439:0
2,071 shares0Common StockSEC:0001209191-23-031191:0
4,024 shares0Common StockSEC:0001127602-22-012835:0
6 of 6 declarations
